Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1866 1
1879 1
1881 1
1901 1
1902 1
1905 2
1915 1
1940 1
1943 2
1945 2
1946 5
1947 2
1950 2
1951 5
1952 4
1953 1
1954 2
1956 1
1957 1
1958 1
1959 2
1960 3
1961 4
1962 5
1963 6
1964 8
1965 13
1966 8
1967 5
1968 12
1969 7
1970 9
1971 5
1972 6
1973 10
1974 3
1975 6
1976 12
1977 7
1978 17
1979 17
1980 17
1981 10
1982 16
1983 18
1984 13
1985 15
1986 17
1987 20
1988 26
1989 29
1990 26
1991 32
1992 29
1993 39
1994 45
1995 46
1996 55
1997 59
1998 76
1999 60
2000 69
2001 77
2002 69
2003 75
2004 99
2005 109
2006 142
2007 162
2008 167
2009 158
2010 198
2011 248
2012 260
2013 307
2014 369
2015 377
2016 366
2017 427
2018 626
2019 700
2020 776
2021 825
2022 806
2023 770
2024 473

Text availability

Article attribute

Article type

Publication date

Search Results

8,381 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Dibash
Page 1
Herpes simplex virus gene therapy for dystrophic epidermolysis bullosa (DEB).
Epstein AL, Haag-Molkenteller C. Epstein AL, et al. Cell. 2023 Aug 17;186(17):3523-3523.e1. doi: 10.1016/j.cell.2023.07.031. Cell. 2023. PMID: 37595560
The FDA has recently approved Krystal biotech's beremagene geperpavec (B-VEC, Vyjuvek) to treat the wounds of dystrophic epidermolysis bullosa (DEB) patients. This represents a giant step, not only toward the treatment of this devastating disease, but also for the whole fi …
The FDA has recently approved Krystal biotech's beremagene geperpavec (B-VEC, Vyjuvek) to treat the wounds of dystrophic epidermolysis bullo …
DEB-TACE: a standard review.
Melchiorre F, Patella F, Pescatori L, Pesapane F, Fumarola E, Biondetti P, Brambillasca P, Monaco C, Ierardi AM, Franceschelli G, Carrafiello G. Melchiorre F, et al. Future Oncol. 2018 Dec;14(28):2969-2984. doi: 10.2217/fon-2018-0136. Epub 2018 Jul 10. Future Oncol. 2018. PMID: 29987957 Review.
This aspect justifies the immediate success of DEB-TACE, that nowadays represents one of the most used treatments for unresectable hepatocellular carcinoma. ...In this review, we describe the available microspheres and report the results of the main comparative studies, to …
This aspect justifies the immediate success of DEB-TACE, that nowadays represents one of the most used treatments for unresectable he …
Innovations in the Treatment of Dystrophic Epidermolysis Bullosa (DEB): Current Landscape and Prospects.
Hou PC, Del Agua N, Lwin SM, Hsu CK, McGrath JA. Hou PC, et al. Ther Clin Risk Manag. 2023 Jun 14;19:455-473. doi: 10.2147/TCRM.S386923. eCollection 2023. Ther Clin Risk Manag. 2023. PMID: 37337559 Free PMC article. Review.
Dystrophic epidermolysis bullosa (DEB) is one of the major types of EB, a rare hereditary group of trauma-induced blistering skin disorders. ...DEB can be subclassified into dominant (DDEB) and recessive (RDEB) forms. ...
Dystrophic epidermolysis bullosa (DEB) is one of the major types of EB, a rare hereditary group of trauma-induced blistering skin dis …
A simple DEB-based ecosystem model.
van der Meer J, Hin V, van Oort P, van de Wolfshaar KE. van der Meer J, et al. Conserv Physiol. 2022 Aug 6;10(1):coac057. doi: 10.1093/conphys/coac057. eCollection 2022. Conserv Physiol. 2022. PMID: 35949258 Free PMC article.
A minimum stoichiometric carbon and nitrogen model of an entire ecosystem based on Dynamic Energy Budget (DEB) theory is presented. The ecosystem contains nutrients, producers, consumers, decomposers and detritus. ...The resulting ontogenetic symmetry implies that complica …
A minimum stoichiometric carbon and nitrogen model of an entire ecosystem based on Dynamic Energy Budget (DEB) theory is presented. T …
Dystrophic Epidermolysis Bullosa.
Pfendner EG, Lucky AW. Pfendner EG, et al. 2006 Aug 21 [updated 2018 Sep 13]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. 2006 Aug 21 [updated 2018 Sep 13]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. PMID: 20301481 Free Books & Documents. Review.
CLINICAL CHARACTERISTICS: Dystrophic epidermolysis bullosa (DEB) is a genetic skin disorder affecting skin and nails that usually presents at birth. DEB is divided into two major types depending on inheritance pattern: recessive dystrophic epidermolysis bullosa (RDE …
CLINICAL CHARACTERISTICS: Dystrophic epidermolysis bullosa (DEB) is a genetic skin disorder affecting skin and nails that usually pre …
Transradial versus transfemoral arterial access in DEB-TACE for hepatocellular carcinoma.
Ghosh A, Gupta V, Al Khalifah A, Akhter NM. Ghosh A, et al. J Clin Imaging Sci. 2022 Jul 15;12:38. doi: 10.25259/JCIS_47_2022. eCollection 2022. J Clin Imaging Sci. 2022. PMID: 36128344 Free PMC article.
This retrospective study compares the efficacy of this approach versus transfemoral access in hepatocellular carcinoma (HCC) patients who underwent drug-eluting bead transarterial chemoembolization (DEB-TACE). MATERIALS AND METHODS: A total of 130 HCC patients underwent 14 …
This retrospective study compares the efficacy of this approach versus transfemoral access in hepatocellular carcinoma (HCC) patients who un …
DEB-FAPy-dG Adducts of 1,3-Butadiene: Synthesis, Structural Characterization, and Formation in 1,2,3,4-Diepoxybutane Treated DNA.
Pujari SS, Jokipii Krueger CC, Chao C, Hutchins S, Hurben AK, Boysen G, Tretyakova N. Pujari SS, et al. Chemistry. 2022 Jan 13;28(3):e202103245. doi: 10.1002/chem.202103245. Epub 2021 Dec 2. Chemistry. 2022. PMID: 34767297 Free PMC article.
Here we report the first synthesis and structural characterization of DEB-FAPy-dG adducts. Authentic standards of DEB-FAPy-dG and its (15) N(3) -labeled analogue were used for the development of a quantitative nanoLC-ESI(+) -HRMS/MS method, allowing for adduct detec …
Here we report the first synthesis and structural characterization of DEB-FAPy-dG adducts. Authentic standards of DEB-FAPy-dG …
Integrating dynamic energy budget (DEB) theory with traditional bioenergetic models.
Nisbet RM, Jusup M, Klanjscek T, Pecquerie L. Nisbet RM, et al. J Exp Biol. 2012 Mar 15;215(Pt 6):892-902. doi: 10.1242/jeb.059675. J Exp Biol. 2012. PMID: 22357583 Free article. Review.
A 'standard' DEB model describes the performance (growth, development, reproduction, respiration, etc.) of all life stages of an animal (embryo to adult), and predicts both intraspecific and interspecific variation in physiological rates. ...These less abstract models are …
A 'standard' DEB model describes the performance (growth, development, reproduction, respiration, etc.) of all life stages of an anim …
Drug-eluting balloons in coronary interventions: the quiet revolution?
Alfonso F, García-Guimaraes M, Navarrete G, Cuesta J, Bastante T, Benedicto A, Rivero F, Cortese B. Alfonso F, et al. Expert Opin Drug Deliv. 2017 Jul;14(7):841-850. doi: 10.1080/17425247.2017.1245291. Epub 2016 Oct 19. Expert Opin Drug Deliv. 2017. PMID: 27718756 Review.
Drug-eluting balloons (DEB) may be considered as a 'quiet revolution' in percutaneous coronary interventions. ...Areas covered: Review of DEB efficacy in patients with coronary de novo lesions and in-stent restenosis (ISR). ...
Drug-eluting balloons (DEB) may be considered as a 'quiet revolution' in percutaneous coronary interventions. ...Areas covered: Revie …
1,3-Butadiene: II. Genotoxicity profile.
Albertini RJ, Carson ML, Kirman CR, Gargas ML. Albertini RJ, et al. Crit Rev Toxicol. 2010 Oct;40 Suppl 1:12-73. doi: 10.3109/10408444.2010.507182. Crit Rev Toxicol. 2010. PMID: 20868267 Review.
EB, EBD, and DEB are DNA reactive, forming a variety of adducts. All three metabolites are genotoxic in vitro and in vivo, with relative mutagenic potencies of DEB >> EB > EBD. DEB also effectively produces gene deletions and chromosome a …
EB, EBD, and DEB are DNA reactive, forming a variety of adducts. All three metabolites are genotoxic in vitro and in vivo, with relat …
8,381 results